ERBB2 and breast cancer: The combination therapy did not add toxicity over trastuzumab alone, nevertheless, this combination did not show clinical benefit in the intention-to-treat population of patients with HER2+ BC (p = 0.18), although a significant improvement in DFS was seen in the TNBC population (p = 0.01) [121].